Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study

Autor: Caroline Feys, Johannes Drach, Zafer Gulbas, Evangelos Terpos, Alois Lang, Gabriele Armbrecht, Meral Beksac, Olga Meltem Akay, Gülsan Türköz Sucak, Anna Potamianou, Orhan Sezer, Nathalie Allietta, Tulin Firatli Tuglular, Werner Linkesch, Robert Olie, Tobias Dechow, Catherine Couturier, Torben Plesner, Roman Hájek, Seckin Cagirgan, John A. Snowden, Hareth Nahi, Ayşen Timurağaoğlu

Publikováno v: Sezer, O, Beksac, M, Hajek, R, Sucak, G, Cagirgan, S, Linkesch, W, Meltem Akay, O, Gülbas, Z, Nahi, H, Plesner, T, Snowden, J A, Timurağaoğlu, A, Dechow, T, Lang, A, Tuğlular, T, Drach, J, Armbrecht, G, Potamianou, A, Couturier, C, Olie, R A, Feys, C, Allietta, N & Terpos, E 2017, ' Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease : a randomized phase II study ', British Journal of Haematology, vol. 178, no. 1, pp. 61-71 . https://doi.org/10.1111/bjh.14637

Summary This phase II study explored the effects of bortezomib consolidation versus observation on myeloma-related bone disease in patients who had a partial response or better after frontline high-dose therapy and autologous stem cell transplantatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea16c54ffea099edd180db6ff5e7e86a
https://avesis.gazi.edu.tr/publication/details/86e8d73e-6d04-4357-9009-c750f984d2ac/oai

Improved tumor response and survival outcomes with post-transplant bortezomib (Btz) consolidation versus observation (Obs) alone in patients with newly diagnosed multiple myeloma (MM): Results from a randomized, open-label, multicenter, parallel-group phase 2 study

Autor: Gabriele Armbrecht, John A. Snowden, Werner Linkesch, Nathalie Allietta, Meral Beksac, Hareth Nahi, Seckin Cagirgan, Catherine Couturier, Olga Meltem Akay, Torben Plesner, Robert Olie, Gülsan Türköz Sucak, Caroline Feys, E. Terpos, Roman Hájek, Zafer Gulbas, Anna Potamianou, O. Sezer

Publikováno v: Sezer, O, Terpos, E, Hajek, R, Sucak, G, Cagirgan, S, Linkesch, W, Akay, O M, Armbrecht, G, Plesner, T, Snowden, J A, Nahi, H, Gulbas, Z, Potamianou, A, Couturier, C, Olie, R, Feys, C, Allietta, N & Beksac, M 2015, ' Improved tumor response and survival outcomes with post-transplant bortezomib (Btz) consolidation versus observation (Obs) alone in patients with newly diagnosed multiple myeloma (MM) : Results from a randomized, open-label, multicenter, parallel-group phase 2 study ', Clinical Lymphoma Myeloma and Leukemia, vol. 15, no. S3, pp. e129-e130 . https://doi.org/10.1016/j.clml.2015.07.323

and showed evidence of disease in 145 (93%). After a median follow-up of 3.5 years, the median OS for the entire group was 7 months. Untreated and treated patients had median OS of 2 and 8 months, respectively. At least one previous line of therapy f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33200461b426f175b02235f9347a9655
https://doi.org/10.1016/j.clml.2015.07.323

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

Autor: Joan Bladé, Vivien Mitchell, Johannes Drach, Meletios A. Dimopoulos, Ralf Angermund, Paolo Corradini, Adriana Teixeira, Nathalie Allietta, Maria Teresa Petrucci, Igor Wolfgang Blau, Pilar Giraldo, Esther Broer

Publikováno v: British journal of haematology. 160(5)

Summary Multiple myeloma (MM) typically follows a relapsing course with many patients requiring multiple therapies. This single-arm phase 2 study prospectively evaluated the efficacy and safety of bortezomib retreatment in MM patients who had relapse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe7442c93adff0ed4b2453716cbf588
https://pubmed.ncbi.nlm.nih.gov/23293914